Author's response to reviews

Title: High nuclear expression levels of histone-modifying enzymes LSD1 HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients

Authors:

Remco S Derr (r.s.derr@lumc.nl)
Anneke Q van Hoesel (aqvanhoesel@gmail.com)
Anne Benard (a.benard@lumc.nl)
Inès J Goossens-Beumer (i.j.goossens-beumer@lumc.nl)
Anita Sajet (asajet@gmail.com)
N. Geeske Dekker-Ensink (n.g.dekker-ensink@lumc.nl)
Esther M de Kruijf (e.m.de_kruijf@lumc.nl)
Esther Bastiaannet (e.bastiaannet@lumc.nl)
Vincent T.H.B.M. Smit (v.t.h.b.m.smit@lumc.nl)
Cornelis J.H. van de Velde (c.j.h.van_de_velde@lumc.nl)
Peter J.K. Kuppen (p.j.k.kuppen@lumc.nl)

Version: 5
Date: 16 July 2014

Author's response to reviews:

Dear Editor,

On July 7th I have sent you an e-mail with a response to your concerns, but I did not receive any response and no changes were made in my account on the website. Therefore, I upload the response, although the deadline of July 11th has been expired.

E-mail:

For our study population, it is not a matter of exemption. We fully followed Dutch law. To my feeling we had sufficiently explained this in the last version of the manuscript by including the following sentence:

The study was conducted with anonymised patient data according to Dutch law and in agreement with the Dutch Code of Conduct: Proper Secondary Use of Human Tissue (Federation of Biomedical Scientific Societies, the Netherlands), and according to the REMARK guidelines [15].

Please, let me know if this is not clear and on what point.

Kind regards,

Peter Kuppen